Post-approval observational prospective study to evaluate the prevalence of the metabolic syndrome in prostate cancer patients both before and after a 12-monthtreatment with quarterly LHRH analogue formulations (ANAMET Study) First published 04/11/2014 Last updated 02/07/2024 EU PAS number:EUPAS7866 Study Finalised